Targeted Therapies in Cancer by - Oncology-unza

Description

This oncology presentation on targeted therapies provides a detailed overview of the principles, development, and clinical applications of molecularly targeted agents in cancer treatment. The material distinguishes targeted therapies from conventional chemotherapy by focusing on specific molecular targets involved in cancer growth and progression, such as overexpressed proteins (e.g., HER2), mutant proteins (e.g., BRAF V600E), and fusion proteins (e.g., BCR-ABL). The two main categories—small molecule inhibitors (e.g., imatinib, gefitinib) and monoclonal antibodies (e.g., trastuzumab, rituximab, bevacizumab)—are explained, along with their mechanisms, including conjugated antibodies for drug delivery. The presentation also addresses the limitations and side effects of targeted therapies, such as hepatic toxicity, skin reactions, and gastrointestinal issues. This resource is essential for medical students, oncology trainees, and practitioners in Zambia, offering structured, exam-focused content for understanding the evolving landscape of precision oncology within a tertiary medical education context. Download these comprehensive notes for thorough preparation on modern cancer therapeutics.